Actively Recruiting
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Led by Frontera Therapeutics · Updated on 2023-05-15
9
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.
CONDITIONS
Official Title
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and sign the informed consent form
- Female or male aged 8 to 45 years when signing the informed consent form
- Clinically diagnosed with biallelic RPE65 mutation-associated retinal dystrophy
You will not qualify if you...
- Presence of other interfering eye diseases
- Any systemic or eye disease that may cause vision loss
- Evidence of uncontrolled concomitant diseases
- Known active or suspected autoimmune diseases
- Active systemic infection under treatment
- Pregnant or lactating women
- Other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
X
Xinyan Li
CONTACT
M
Minghui Xue
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here